Associations between Khorana score levels and risk components and 6-month risk of VTE in a subdistribution hazard model
| . | Subdistribution hazard ratios* . | |
|---|---|---|
| . | Crude . | Adjusted† . |
| Khorana component | ||
| Pancreas | 2.06 (1.64-2.59) | 2.05 (1.63-2.58) |
| Stomach | 2.23 (1.74-2.87) | 2.25 (1.76-2.89) |
| Lung | 1.36 (1.17-1.59) | 1.26 (1.08-1.48) |
| Lymphoma | 1.13 (0.91-1.41) | 1.10 (0.88-1.37) |
| Gynecologic | 1.18 (0.94-1.49) | 1.19 (0.94-1.50) |
| Bladder | 2.17 (1.58-2.98) | 2.12 (1.55-2.92) |
| Testis | 1.04 (0.54-2.01) | 1.12 (0.58-2.15) |
| Hemoglobin level <10 g/dL or use of erythropoiesis-stimulating agents | 1.19 (0.97-1.46) | 1.13 (0.91-1.39) |
| Platelet count ≥350 × 109/L | 1.15 (1.01-1.31) | 0.94 (0.82-1.08) |
| Leukocyte count >11 × 109/L | 1.73 (1.51-1.99) | 1.63 (1.41-1.88) |
| Body mass index ≥35 kg/m2 | 1.30 (0.78-2.17) | 1.33 (0.79-2.22) |
| Khorana score level | ||
| 0 | Ref. | |
| 1 | 1.69 (1.42-2.01) | |
| 2 | 2.29 (1.92-2.74) | |
| 3 | 2.68 (2.17-3.32) | |
| 4 | 3.29 (2.28-4.72) | |
| 5-6 | 5.66 (2.30-13.93) | |
| . | Subdistribution hazard ratios* . | |
|---|---|---|
| . | Crude . | Adjusted† . |
| Khorana component | ||
| Pancreas | 2.06 (1.64-2.59) | 2.05 (1.63-2.58) |
| Stomach | 2.23 (1.74-2.87) | 2.25 (1.76-2.89) |
| Lung | 1.36 (1.17-1.59) | 1.26 (1.08-1.48) |
| Lymphoma | 1.13 (0.91-1.41) | 1.10 (0.88-1.37) |
| Gynecologic | 1.18 (0.94-1.49) | 1.19 (0.94-1.50) |
| Bladder | 2.17 (1.58-2.98) | 2.12 (1.55-2.92) |
| Testis | 1.04 (0.54-2.01) | 1.12 (0.58-2.15) |
| Hemoglobin level <10 g/dL or use of erythropoiesis-stimulating agents | 1.19 (0.97-1.46) | 1.13 (0.91-1.39) |
| Platelet count ≥350 × 109/L | 1.15 (1.01-1.31) | 0.94 (0.82-1.08) |
| Leukocyte count >11 × 109/L | 1.73 (1.51-1.99) | 1.63 (1.41-1.88) |
| Body mass index ≥35 kg/m2 | 1.30 (0.78-2.17) | 1.33 (0.79-2.22) |
| Khorana score level | ||
| 0 | Ref. | |
| 1 | 1.69 (1.42-2.01) | |
| 2 | 2.29 (1.92-2.74) | |
| 3 | 2.68 (2.17-3.32) | |
| 4 | 3.29 (2.28-4.72) | |
| 5-6 | 5.66 (2.30-13.93) | |